Use of Biological Disease-Modifying Antirheumatic Drugs (bDMARD) Therapy in Rheumatoid Arthritis: A Review of Side Effects and Immunological Mechanisms
English
DOI:
https://doi.org/10.70471/y4mv8218Keywords:
Rheumatoid arthritis, bDMARD, side effects, immunologyAbstract
Rheumatoid arthritis (AR) is a chronic autoimmune disease that causes symmetrical inflammation of small and large joints and other organs. AR treatment has evolved with the introduction of Biological Disease-Modifying Antirheumatic Drugs (bDMARD) that target specific immunological pathways in AR pathogenesis thereby increasing the effectiveness of therapy. The study aims to review the side effects of bDMARD and its immunological mechanisms. The method used was a literature review by searching for articles from scientific databases related to the side effects and immunological mechanisms of bDMARD in AR. Results suggest that bDMARD are effective in controlling inflammation and preventing joint damage, but have significant side effects, including an increased risk of serious infections such as tuberculosis reactivation and opportunistic infections such as shingles. In addition, there is a risk of malignancy, major cardiovascular events (MACE), gastrointestinal disorders, and hematological disorders such as neutropenia. The immunological mechanism of bDMARD involves inhibition of pro-inflammatory cytokines such as TNF-α and IL-6, as well as suppression of T cell activation and B cells that play a role in AR inflammation. In conclusion, although bDMARD provide significant therapeutic benefits in AR treatment, monitoring side effects ensures long-term safety.
Downloads
References
Andisari, H. E. (2018). Current Therapy of Rheumatoid Arthritis (part 2). Oceana Biomedicina Journal, 1(2)(2), 90–102.
Barbulescu, A., Delcoigne, B., Askling, J., & Frisell, T. (2020). Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: A nationwide cohort study. RMD Open, 6(2), 1–10. https://doi.org/10.1136/rmdopen-2020-001201
Bonek, K., Roszkowski, L., Massalska, M., Maslinski, W., & Ciechomska, M. (2021). Biologic drugs for rheumatoid arthritis in the context of biosimilars, genetics, epigenetics and COVID-19 treatment. Cells, 10(2), 1–26. https://doi.org/10.3390/cells10020323
Bullock, J., Rizvi, S. A. A., Saleh, A. M., Ahmed, S. S., Do, D. P., Ansari, R. A., & Ahmed, J. (2019). Rheumatoid arthritis: A brief overview of the treatment. Medical Principles and Practice, 27(6), 501–507. https://doi.org/10.1159/000493390
Burke, B. R. A., Pharm, D., White, N. D., Pharm, D., Farrell, J. F., Pharm, D., Galloway, B. E., Pharm, D., Minger, H., & Pharm, D. (2014). Biologic Disease-Modifying Antirheumatic Drugs. 9–31.
Chaplin, S. (2020). Biological disease‐modifying drugs for rheumatoid arthritis. Prescriber, 31(4), 22–27. https://doi.org/10.1002/psb.1836
Esse, S., Mason, K. J., Green, A. C., & Warren, R. B. (2020). Melanoma Risk in Patients Treated with Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis. JAMA Dermatology, 156(7), 787–794. https://doi.org/10.1001/jamadermatol.2020.1300
Evangelatos, G., Koulouri, V., Iliopoulos, A., & Fragoulis, G. E. (2020). Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Therapeutic Advances in Musculoskeletal Disease, 12, 1–21. https://doi.org/10.1177/1759720X20930116
Findeisen, K. E., Sewell, J., & Ostor, A. J. K. (2021). Biological therapies for rheumatoid arthritis: An overview for the clinician. Biologics: Targets and Therapy, 15, 343–352. https://doi.org/10.2147/BTT.S252575
Hidayat, R., Suryana, B. P. P., Wijaya, L. K., Ariane, A., Hellmi, R. Y., Adnan, E., & Sumariyono. (2021). Diagnosis dan Pengelolaan Artritis Reumatoid. In Perhimpunan Reumatologi Indonesia.
Lopez-Pedrera, C., Barbarroja, N., Patiño-Trives, A. M., Luque-Tévar, M., Collantes-Estevez, E., Escudero-Contreras, A., & Pérez-Sánchez, C. (2020). Effects of biological therapies on molecular features of rheumatoid arthritis. International Journal of Molecular Sciences, 21(23), 1–30. https://doi.org/10.3390/ijms21239067
Min, H. K., Kim, S. H., Kim, H. R., & Lee, S. H. (2022). Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis. International Journal of Molecular Sciences, 23(22). https://doi.org/10.3390/ijms232213913
Ogata, A., Kato, Y., Higa, S., & Yoshizaki, K. (2019). IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Modern Rheumatology, 29(2), 258–267. https://doi.org/10.1080/14397595.2018.1546357
Payandeh, Z., Bahrami, A. A., Hoseinpoor, R., Mortazavi, Y., Rajabibazl, M., Rahimpour, A., Taromchi, A. H., & Khalil, S. (2019). The applications of anti-CD20 antibodies to treat various B cells disorders. Biomedicine and Pharmacotherapy, 109(July 2018), 2415–2426. https://doi.org/10.1016/j.biopha.2018.11.121
Peasah, S. K., Swart, E. C. S., Huang, Y., Kane-Gill, S. L., Seybert, A. L., Patel, U., Manolis, C., & Good, C. B. (2024). Disease-Modifying Medications in Patients with Rheumatoid Arthritis in the USA: Trends from 2016 to 2021. Drugs - Real World Outcomes, 11(2), 241–249. https://doi.org/10.1007/s40801-024-00416-3
Rempenault, C., Lukas, C., Combe, B., Herrero, A., Pane, I., Schaeverbeke, T., Wendling, D., Pham, T., Gottenberg, J. E., Mariette, X., & Morel, J. (2022). Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology (United Kingdom), 61(3), 953–962. https://doi.org/10.1093/rheumatology/keab438
Sepriano, A., Kerschbaumer, A., Bergstra, S. A., Smolen, J. S., Van Der Heijde, D., Caporali, R., Edwards, C. J., Verschueren, P., De Souza, S., Pope, J., Takeuchi, T., Hyrich, K., Winthrop, K. L., Aletaha, D., Stamm, T., Schoones, J. W., & Landewé, R. B. M. (2022). Safety of synthetic and biological DMARDs: A systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 82(1), 107–118. https://doi.org/10.1136/ard-2022-223357
Small, A., Lowe, K., & Wechalekar, M. D. (2023). Immune checkpoints in rheumatoid arthritis: progress and promise. Frontiers in Immunology, 14(November), 1–9. https://doi.org/10.3389/fimmu.2023.1285554
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., Van Vollenhoven, R. F., De Wit, M., Aletaha, D., Aringer, M., Askling, J., Balsa, A., Boers, M., Den Broeder, A. A., Buch, M. H., Buttgereit, F., Caporali, R., … Van Der Heijde, D. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 79(6), S685–S699. https://doi.org/10.1136/annrheumdis-2019-216655
Tarp, S., Furst, D. E., Boers, M., Luta, G., Bliddal, H., Tarp, U., Asmussen, K. H., Brock, B., Dossing, A., Jørgensen, T. S., Thirstrup, S., & Christensen, R. (2017). Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: A systematic review meta-analysis. Rheumatology (United Kingdom), 56(3), 417–425. https://doi.org/10.1093/rheumatology/kew442
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Jody Yusuf, Ainur Rofiq, Aditya Sofyansyah Hermaya, M Dian Islami (Author)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
